OmniComm buys more EDC assets
The acquisition follows OmniComm’s purchase of eResearch Technologies’ (ERT) EDC assets. By making the acquisitions OmniComm believes it has strengthened and broadened the scope of its offering in a market that it predicts will enjoy long-term growth.
Discussing the acquisition of Logos’ assets, Cornelis Wit, OmniComm's CEO, explained: “Larger pharmaceutical companies in particular will be a prime consumer of this product.
“This combined with our recent acquisition of ERT’s data capture unit, positions us well to offer our clients a wide array of state of the art, cost-effective tools to capture and track outcomes of clinical trials."
OmniComm’s acquisition of assets from Logos moves it into the Phase I trials market, which it has identified as a sector that few companies specialise in.
Data collection in Phase I is very-time controlled and this means EDC systems need different abilities. To tailor its EDC system to Phase I Logos uses proactive data collection, which OmniComm regards as imperative for early-stage trials.
Logos is one of just three companies that markets EDC systems with proactive data collection, according to OmniComm. Consequently, the acquisition of these assets puts OmniComm in a strong position in the Phase I EDC market.
Citing Health Industry Insights OmniComm states that the Phase I EDC market will be worth $120m (€83.4m) by 2010.
Furthermore, OmniComm believes the Phase I market is one of the fastest growing segments of clinical research and that this will translate into increased demand for early-stage EDC systems.
The acquisition will be operated by OmniComm’s subsidiary in the UK.
